FDA Approved Drugs by Name
Company: Genentech

Search by brand name for drugs approved by the Food and Drug Administration (FDA) for sale in the United States. Each listing contains a brief description of the indication for use. Click on the drug name for a complete product profile, including general information, clinical trial results, side effects and manufacture information.

Actemra (ocilizumab)

For the treatment of Polyarticular Juvenile Idiopathic Arthritis

Actemra (tocilizumab)

For the treatment of rheumatoid arthritis

Actemra (tocilizumab)

For the treatment of systemic juvenile idiopathic arthritis

Actemra (tocilizumab) injection

For the treatment of CAR T cell-induced severe or life-threatening cytokine release syndrome

Avastin (bevacizumab)

For the treatment of metastatic carcinoma of the colon or rectum

Avastin (bevacizumab)

For the treatment of renal cell carcinoma

Cotellic (cobimetinib)

For the treatment of BRAF V600E or V600K melanoma

Erivedge (vismodegib)

For the treatment of basal cell carcinoma

Gazyva (obinutuzumab)

For the treatment of previously untreated chronic lymphocytic leukemia

Hemlibra (emicizumab-kxwh)

For the prevention or reduction of bleeding episodes in patients with hemophilia A

Herceptin

Treatment for metastatic breast cancer

Herceptin (trastuzumab)

For the treatment of gastric cancer

Kadcyla (ado-trastuzumab emtansine)

For the treatment of HER2-positive metastatic breast cancer

Lucentis (ranibizumab injection)

For the treatment of diabetic macular edema

Lucentis (ranibizumab)

For the treatment of neovascular (wet) age related macular degeneration

Nutropin (somatropin-rDNA origin)

Treatment for growth hormone deficiency

Nutropin (somatropin-rDNA origin)

Treatment that consists of recombinant growth hormone product

Ocrevus (ocrelizumab)

For the treatment of multiple sclerosis

Perjeta (pertuzumab)

For the first-line treatment of HER2+ metastatic breast cancer

Pulmozyme (dornase alfa)

Treatment for cystic fibrosis

Pulmozyme (dornase alfa)

Treatment for cystic fibrosis patients with advanced disease

Tecentriq (atezolizumab)

For the treatment of urothelial carcinoma and metastatic non-small cell lung cancer

Xolair (omalizumab)

For the treatment of asthma